ESMO 2022: Lung roundup

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN

Tislelizumab demonstrates non-inferior OS compared to sorafenib for treating hepatocellular carcinoma

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer

ESMO 2022: Breast and ovarian trial analysis

ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer

Pembrolizumab/carboplatin/paclitaxel combo shows antitumour activity in first-line recurrent/metastatic HNSCC

ESMO 2022: Highlights, commentary and analysis

Ideal duration of androgen deprivation therapy with post-operative radiotherapy for prostate cancer

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

ESMO 2022: Renal roundup

Fruquintinib provides improvement in overall survival for refractory mCRC

ESMO 2022: Breast cancer highlights

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO

Emerging systemic therapies in rare urothelial cancer variants

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

Adjuvant nivolumab plus ipilimumab vs placebo for localised renal cell carcinoma at high risk of relapse after nephrectomy

A new era of early cancer detection with blood test may change cancer screening paradigms

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC

Nivolumab ipilimumab combo does not improve DFS for RCC after nephrectomy

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular carcinoma

Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement

Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma

New era of early cancer detection blood tests on the horizon

Hyperthermic intraperitoneal chemo for locally advanced colon cancer

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Lasofoxifene shows promise for women with ESR1-mutated mBC

Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy

Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

Metastatic breast cancer endpoints for survival: rwPFS and TTNT

New data presented at ESMO for multi-cancer early detection

Perioperative nivolumab did not improve RFS in RCC patients at high risk for recurrence

Atezolizumab added to chemo fails to improve PFS in relapsed ovarian cancer

Nirogacestat demonstrates clinically significant improvement in PFS versus placebo for progressing desmoid tumours

Scientists discover mechanism of action and an actionable inflammatory axis for air pollution induced NSCLC

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma

Olaparib continues to show positive results in advanced ovarian cancer - 7 year data

How air pollution may trigger lung cancer in never-smokers

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Nirogacestat success for desmoid tumours